Genistein-Derived ROS-Responsive Nanoparticles Relieve Colitis by Regulating Mucosal Homeostasis

Wentao Fan,Shuo Zhang,Yuting Wu,Tao Lu,Jiwen Liu,Xiuyun Cao,Shuhui Liu,Liping Yan,Xizhi Shi,Guangliang Liu,Chaobo Huang,Suquan Song
DOI: https://doi.org/10.1021/acsami.1c09215
2021-08-23
Abstract:Disruption of intestinal homeostasis is an important event in the development of inflammatory bowel disease (IBD), and genistein (GEN) is a candidate medicine to prevent IBD. However, the clinical application of GEN is restricted owing to its low oral bioavailability. Herein, a reactive oxygen species (ROS)-responsive nanomaterial (defined as GEN-NP2) containing superoxidase dismutase-mimetic temporally conjugated β-cyclodextrin and 4-(hydroxymethyl)phenylboronic acid pinacol ester-modified GEN was prepared. GEN-NP2 effectively delivered GEN to the inflammation site and protected GEN from rapid metabolism and elimination in the gastrointestinal tract. In response to high ROS levels, GEN was site-specifically released and accumulated at inflammatory sites. Mechanistically, GEN-NP2 effectively increased the expression of estrogen receptor β (ERβ), simultaneously reduced the expression of proinflammatory mediators (apoptosis-associated speck-like protein containing a CARD (ASC) and Caspase1-p20), attenuated the infiltration of inflammatory cells, promoted autophagy of intestinal epithelial cells, inhibited the secretion of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), modulated the gut microbiota, and ultimately alleviated colitis. In addition, the oral administration of these nanoparticles showed excellent safety, thereby providing confidence in the further development of precise treatments for IBD.The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c09215.The synthetic route of β-cyclodextrin (β-CD) conjugated with Tempol (TPL) units (TCD); characterization of TCD by FT-IR and 1H-NMR spectroscopy; design and observation of GEN-NPs; characterization of GEN-NPs; ROS-scavenging capability of different materials; cellular uptake and in vitro cytotoxicity studies of GEN-NPs; in vitro antioxidative stress activities and in vitro cytotoxicity studies of GEN-NPs; GEN-NPs regulate autophagy-inflammasome signaling pathway in NCM-460 cells; GEN-NPs preferentially localize to the inflamed colon; toxicity study of oral administration of GEN-NPs in mice; and analysis of the inflammation and gut microbiota in colitis mice after treatment with GEN-NPs (PDF)This article has not yet been cited by other publications.
materials science, multidisciplinary,nanoscience & nanotechnology
What problem does this paper attempt to address?
The paper aims to address key issues in the treatment of inflammatory bowel disease (IBD), particularly how to improve the effective delivery and bioavailability of drugs at inflammation sites. The study found that soy isoflavone genistein (GEN) has potential preventive and therapeutic effects on IBD, but its clinical application is limited due to its low oral bioavailability. Therefore, researchers developed a reactive oxygen species (ROS)-responsive nanomaterial (defined as GEN-NP2), which can effectively deliver GEN to inflammation sites and protect GEN from rapid metabolism and elimination in the gastrointestinal tract. Mechanistically, GEN-NP2 can increase the expression of estrogen receptor β (ERβ), reduce the expression of pro-inflammatory mediators, promote autophagy in intestinal epithelial cells, inhibit the secretion of inflammatory cytokines, and regulate the gut microbiota, ultimately alleviating colitis symptoms. Additionally, the oral administration of these nanoparticles demonstrated excellent safety, providing confidence for the precise treatment of IBD.